Epigallocatechin-3-gallate inhibits TF and TNF-α expression induced by the anti-β 2 GPI / β 2 GPI complex in human THP-1 cells
暂无分享,去创建一个
Hong Zhou | Hongxiang Xie | Ting Wang | Jingjing Liu | Xiaolei Zhang | M. Yuan | XU Ya
[1] S. H. Lee,et al. Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. , 2013, European journal of cancer.
[2] Xue-Jun Song,et al. WNT signaling underlies the pathogenesis of neuropathic pain in rodents. , 2013, The Journal of clinical investigation.
[3] Hong Zhou,et al. Both NF-κB and c-Jun/AP-1 involved in anti-β2GPI/β2GPI-induced tissue factor expression in monocytes , 2013, Thrombosis and Haemostasis.
[4] Hong Zhou,et al. Anti-β(2)GPI/β(2)GPI induced TF and TNF-α expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. , 2013, Molecular immunology.
[5] Hong Zhou,et al. Activation of MAPKs in the anti-β2GPI/β2GPI-induced tissue factor expression through TLR4/IRAKs pathway in THP-1 cells. , 2012, Thrombosis research.
[6] A. Schulz,et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial , 2012, The Lancet.
[7] M. Khamashta,et al. Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome , 2012, Seminars in Thrombosis & Hemostasis.
[8] Hui-Yi Lin,et al. (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells. , 2012, Journal of agricultural and food chemistry.
[9] Hong Zhou,et al. Involvement of IRAKs and TRAFs in anti-β2GPI/β2GPI-induced tissue factor expression in THP-1 cells , 2011, Thrombosis and Haemostasis.
[10] G. Espinosa,et al. Management of refractory cases of catastrophic antiphospholipid syndrome. , 2011, Autoimmunity reviews.
[11] J. Musial,et al. Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state , 2011, Rheumatology International.
[12] M. Petri. Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody–Positive Patients , 2011, Current rheumatology reports.
[13] H. Zhou,et al. Toll‐like receptor (TLR)‐4 mediates anti‐β2GPI/β2GPI‐induced tissue factor expression in THP‐1 cells , 2011, Clinical and experimental immunology.
[14] Zhiwei Wang,et al. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer , 2010, Cancer and Metastasis Reviews.
[15] A. Akhmedov,et al. Laminin receptor activation inhibits endothelial tissue factor expression. , 2010, Journal of molecular and cellular cardiology.
[16] O. Neth,et al. Infant With Probable Catastrophic Antiphospholipid Syndrome Successfully Managed With Rituximab , 2010, Pediatrics.
[17] M. Khamashta,et al. Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future , 2010, European journal of clinical investigation.
[18] N. Mackman,et al. Role of tissue factor in thrombosis in antiphospholipid antibody syndrome , 2010, Lupus.
[19] Hong Zhou,et al. Annexin A2 mediates anti-β2GPI/β2GPI-induced tissue factor expression on monocytes , 2009 .
[20] J. Brosens,et al. ORIGINAL ARTICLE: Antiphospholipid Antibodies Induce a Pro‐Inflammatory Response in First Trimester Trophoblast Via the TLR4/MyD88 Pathway , 2009, American journal of reproductive immunology.
[21] M. Karin,et al. Regulation and function of NF-kappaB transcription factors in the immune system. , 2009, Annual review of immunology.
[22] W. Yeh,et al. LPS/TLR4 signal transduction pathway. , 2008, Cytokine.
[23] Chunli Shao,et al. The roles of MAPKs in disease , 2008, Cell Research.
[24] J. Um,et al. Epigallocatechin-3-gallate suppresses NF-κB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells , 2007 .
[25] E. García-Latorre,et al. In Vivo Effects of an Inhibitor of Nuclear Factor‐Kappa B on Thrombogenic Properties of Antiphospholipid Antibodies , 2007, Annals of the New York Academy of Sciences.
[26] Xiaowei Liu,et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies , 2007, Annals of the rheumatic diseases.
[27] K. Kang,et al. Suppression of MyD88- and TRIF-dependent signaling pathways of Toll-like receptor by (-)-epigallocatechin-3-gallate, a polyphenol component of green tea. , 2006, Biochemical pharmacology.
[28] M. Goodrick,et al. Antiphospholipid syndrome: a series of surgical emergencies and the current evidence for its management. , 2006, Annals of the Royal College of Surgeons of England.
[29] M. Martinuzzo,et al. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies , 2005, Lupus.
[30] A. Wolberg,et al. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. , 2004, Blood.
[31] P. D. de Groot,et al. beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome. , 2004, Clinical immunology.
[32] P. D. de Groot,et al. Antiphospholipid antibodies: update on detection, pathophysiology, and treatment , 2004, Current opinion in hematology.
[33] W. Faulk,et al. Antiphospholipid antibodies: discovery, definitions, detection and disease. , 2003, Progress in lipid research.
[34] K. Yoon. Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in antiphospholipid antibody (Hughes') syndome. , 2002, The Journal of rheumatology.
[35] A. Gharavi,et al. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. , 1999, Journal of immunology.
[36] Xiaowei Liu,et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. , 1999, Circulation.
[37] J. Barker,et al. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. , 1996, Circulation.
[38] Chan Jun-mi,et al. International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome(APS) , 2008 .
[39] J. Um,et al. Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells. , 2007, International archives of allergy and immunology.
[40] Y. Oh,et al. Epigallocatechin-3-gallate, constituent of green tea, suppresses the LPS-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and NF-kappaB. , 2004, Biochemical and biophysical research communications.
[41] V. Malhotra,et al. Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. , 2004, The Journal of nutrition.
[42] H. Fujiki,et al. Mechanisms of cancer prevention by tea polyphenols based on inhibition of TNF-α expression , 2000 .
[43] Y. L. Lin,et al. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. , 1997, Molecular pharmacology.